Global Rhematoid Arthritis Drugs Market 2016-2020

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding RA
Etiology and pathophysiology
Signs and symptoms
Diagnosis
Disease management
Economic burden of RA
Epidemiology

PART 06: Impact of biologics in RA

PART 07: Pipeline portfolio
Novel mechanisms targeted by pipeline candidates
Clinical trials for RA

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by drug class
DMARDs
NSAIDs
Corticosteroids
Analgesics
Others
Global DMARDs market
Global NSAIDs market
Global corticosteroids market
Global analgesics market

PART 10: Market segmentation by MOA
TNF inhibitors
IL-1 blockers
JAK inhibitors
Selective costimulation modulators

PART 11: Market segmentation by type of molecule
Biologics
Small molecules

PART 12: Market segmentation by ROA
Oral
Parenteral
Topical

PART 13: Market segmentation by dosage form
Solid
Liquid
Semi-solid

PART 14: Geographical segmentation
RA drugs market in Americas
RA drugs market in US
RA drugs market in EMEA
RA drugs market in Germany
RA drugs market in UK
RA drugs market in Spain
RA drugs market in Italy
RA drugs market in France
Rheumatoid arthritis drugs market in APAC
RA drugs market in Japan
RA drugs market in Australia
RA drugs market in India
RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers
Growing older population
Market dominance of biologics
Promising drug pipeline
Changing lifestyle patterns
Advances in diagnosis technology

PART 17: Impact of drivers

PART 18: Market challenges
Increasing costs of biologicals
Loss of patent exclusivity of branded therapies
Use of complementary and alternative medicines (CAMs)
Adverse effects of drugs
Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends
Emergence of biosimilars
Patient assistance programs
Popularity of off-label and traditional treatment options
Strategic alliances
Increase in public awareness

PART 21: Vendor landscape
Competitive scenario
Market share analysis 2015
AbbVie
Amgen
BMS
F. Hoffmann-La Roche
Johnson & Johnson
Pfizer
Other prominent vendors

PART 22: Appendix4
List of abbreviations4

PART 23: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for RA drugs
Exhibit 03: Classification of RA based on disease severity
Exhibit 04: Classification of RA based on disease severity 2016
Exhibit 05: Etiology and pathophysiology of RA
Exhibit 06: Signs and symptoms of RA
Exhibit 07: Diagnostic tests for RA
Exhibit 08: Treatment options for RA
Exhibit 09: Non-pharmacological therapies used for RA
Exhibit 10: Pharmacotherapy therapy for RA
Exhibit 11: Drugs used to treat RA
Exhibit 12: Classification of surgical treatment for RA
Exhibit 13: Percentage share of treatment of RA 2016
Exhibit 14: Historical milestones in treatment of RA
Exhibit 15: Treatment algorithm for RA
Exhibit 16: Economic burden of RA
Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
Exhibit 20: New cases of RA in UK per year 2016
Exhibit 21: Existing cases of RA in UK
Exhibit 22: Impact of biologics on various sectors
Exhibit 23: Pipeline molecules for RA
Exhibit 24: Novel targets of pipeline candidates
Exhibit 25: Candidates under development: Baricitinib
Exhibit 26: Candidates under development: Decernotinib
Exhibit 27: Candidates under development: CCX354
Exhibit 28: Candidates under development: Sirukumab
Exhibit 29: Candidates under development: Infliximab biosimilar
Exhibit 30: Candidates under development: Secukinumab
Exhibit 31: Candidates under development: Bimekizumab
Exhibit 32: Clinical trials of RA drugs by phase 2016
Exhibit 33: Clinical trials of RA drugs by status 2016
Exhibit 34: Global RA drugs market 2015-2020 ($ billions)
Exhibit 35: Opportunities in RA drugs industry
Exhibit 36: Five forces analysis
Exhibit 37: Global RA drugs market segmentation by drug class
Exhibit 38: Examples of non-biologic DMARDs and biologic DMARDs for RA
Exhibit 39: NSAIDs used to treat RA
Exhibit 40: Market share of global RA drugs market by drug class 2015
Exhibit 41: Global DMARDs market 2015-2020 ($ billions)
Exhibit 42: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 43: Global corticosteroids market 2015-2020 ($ billions)
Exhibit 44: Global analgesics market 2015-2020 ($ billions)
Exhibit 45: Market segmentation of global RA drugs market by MOA
Exhibit 46: Mean percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 47: Global RA drugs market share by MOA 2015
Exhibit 48: Global RA drugs market segmentation by type of molecule
Exhibit 49: Global RA drugs market share by type of molecules 2015
Exhibit 50: Global RA drugs market segmentation by ROA
Exhibit 51: Global RA drugs market segmentation by ROA 2015
Exhibit 52: Global RA drugs market segmentation by dosage form
Exhibit 53: Global RA drugs market segmentation by dosage form 2015
Exhibit 54: Global RA drugs by geography 2015
Exhibit 55: Global RA drugs market by geography 2015-2020 ($ billions)
Exhibit 56: Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 57: RA drugs market in Americas 2015-2020 ($ billions)
Exhibit 58: RA drugs market in Americas by country 2015
Exhibit 59: RA drugs market in US 2015-2020 ($ billions)
Exhibit 60: RA drugs sales in US by drug class 2015
Exhibit 61: Drivers and challenges of RA drugs market in US
Exhibit 62: RA drugs market in EMEA 2015-2020 ($ billions)
Exhibit 63: RA drugs market in EMEA by country 2015
Exhibit 64: RA sales in EMEA by drug class 2015
Exhibit 65: RA drugs market in Germany 2015-2020 ($ billions)
Exhibit 66: RA drugs market in UK 2015-2020 ($ billions)
Exhibit 67: RA drugs market in Spain 2015-2020 ($ millions)
Exhibit 68: RA drugs market in Italy 2015-2020 ($ millions)
Exhibit 69: RA drugs market in France 2015-2020 ($ millions)
Exhibit 70: RA drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: RA drugs market in APAC by country 2015
Exhibit 72: RA drugs market in Japan 2015-2020 ($ billions)
Exhibit 73: RA drugs sales in Japan by drug class 2015
Exhibit 74: Drivers and challenges to growth of RA drugs market in Japan
Exhibit 75: RA drugs market in Australia 2015-2020 ($ millions)
Exhibit 76: RA drugs sales in Australia by drug class 2015
Exhibit 77: Drivers and challenges in RA drugs market in Australia
Exhibit 78: RA drugs market in India 2015-2020 ($ billions)
Exhibit 79: RA sales in India by drug class 2015
Exhibit 80: RA drugs market in China 2015-2020 ($ millions)
Exhibit 81: RA drugs sales in China by drug class 2015
Exhibit 82: Key leading countries
Exhibit 83: Population aged 60 years and over: World, developed and developing regions ($ millions)
Exhibit 84: FDA approval of biologicals
Exhibit 85: List of pipeline molecules
Exhibit 86: Lifestyle factors – Risk of rheumatoid arthritis
Exhibit 87: Impact of drivers
Exhibit 88: Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
Exhibit 89: Approval and patent expiries of top selling biologics
Exhibit 90: CAM therapies for RA
Exhibit 91: Usage of CAM in US
Exhibit 92: Side effects associated with RA
Exhibit 93: Impact of drivers and challenges
Exhibit 94: Patient assistance programs offered by companies
Exhibit 95: Revenue share of RA drugs by vendors 2015
Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
Exhibit 97: Competitive assessment of top RA drugs
Exhibit 98: Revenue share of RA drugs 2015
Exhibit 99: AbbVie: Product segmentation by revenue 2014
Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
Exhibit 103: Sales of Humira in major markets
Exhibit 104: AbbVie: SWOT analysis
Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
Exhibit 108: Amgen: SWOT analysis
Exhibit 109: BMS: Segmentation by revenue 20141
Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
Exhibit 113: Orencia sales for RA in major markets 2014
Exhibit 114: BMS: SWOT analysis
Exhibit 115: RA products by revenue 2014
Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
Exhibit 118: F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
Exhibit 128: Johnson & Johnson: SWOT analysis
Exhibit 129: Pfizer: Rhematoid drugs product segmentation by revenue 2014
Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
Exhibit 133: Pfizer: SWOT analysis

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.